Bulls Proved Right: Hyperion's Ravicti Wins Approval in UCD
By Jennifer Boggs
Managing Editor
Managing Editor
The recent spike in Hyperion Therapeutics Inc.'s stock proved to be warranted Friday, when the FDA issued an approval for Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients, ages 2 and older.